

## PGY2 Infectious Diseases Pharmacy Residency

The PGY2 ID Residency at Wellstar MCG Health (WMCGH) is a 12-month program designed to provide the knowledge and tools necessary to be an expert in ID pharmacotherapy. Program graduates will be prepared for advanced patient care, academia, or other specialized positions in ID, and qualified for ID specialist board certification examination.

### Learning Experiences (required)

- Orientation (4 weeks)
- General ID Consults – I (6 weeks)
- Immunocompromised ID I & II (5 weeks each)
- Microbiology Laboratory (4 weeks)
- Pediatric Infectious Diseases (4 weeks)
- General ID Consults – Advanced (4 weeks)
- Antimicrobial Stewardship and Administration (4 weeks)
- General ID Consults/ Antimicrobial Stewardship (5 weeks)

### Learning Experiences (elective)

- Ambulatory Infectious Diseases (4 weeks)
- Hematopoietic Cell Transplantation/ Antimicrobial Stewardship (4 weeks)

### Longitudinal Activities

- Ryan White Clinic
- Pharmacy Practice and Research (including, but not limited to):
  - Formulary Management & Committee Leadership
  - Infectious Diseases Clinical On-Call Program
  - Weekend Staffing (every 4<sup>th</sup> weekend)
  - Staff Development (Grand Rounds, Journal Club)
  - Research and Quality Improvement
  - Antimicrobial Stewardship

### Highlights

- Complex Patient Populations
  - Solid Organ Transplant
    - Kidney/Pancreas
  - Hematological/Bone Marrow Transplant
  - CAR-T Cell Therapy
  - Children's Hospital of Georgia
  - Level I Trauma Center
  - 8 Intensive Care Units
    - Medical, Neuro, Trauma, Surgical, Cardiovascular, Neonatal
  - Ventricular Assist Device Destination Center
- Interprofessional Opportunities
  - City Wide ID Grand Rounds
    - CME Journal Club
    - CME Case Conference
  - Antimicrobial Subcommittee Leadership
- Research and Academics
  - Robust Clinical Research Department
  - Association with UGA College of Pharmacy and Medical College of Georgia
  - Opportunity to complete a Teaching Certificate through UGA

## Wellstar MCGH PGY2 Infectious Diseases Preceptors and Staff

Josh Eudy, Pharm.D., BCIDP	PGY2 Infectious Diseases Program Director WMCG Antimicrobial Stewardship Committee Co-Chair Infectious diseases/ Antimicrobial Stewardship Pharmacist
Daniel Anderson, Pharm.D., BCIDP	PGY2 Infectious Diseases Program Coordinator Infectious diseases/ Antimicrobial Stewardship Pharmacist
Margaret Oates, Pharm.D., BCPPS	Pediatric Cystic Fibrosis Antimicrobial Stewardship Pharmacist
Amber Ladak, Pharm.D., BCACP, AAHIVP	Clinical HIV Pharmacist
Charity Nora, Pharm.D., BSACP	Digestive Health Ambulatory Pharmacist
Amber Clemmons, Pharm.D., BCOP	PGY2 Oncology Residency Director BMT Clinical Pharmacist Clinical Professor, UGA College of Pharmacy
Jose Vazquez, MD, FACP, FIDSA	Infectious Diseases Department Chief Antimicrobial Stewardship Committee Chair Institution Review Board Chair
Andrew Chao, MD	Assistant Professor, Infectious Diseases Division Infectious Diseases Fellowship Program Director
Anna Zubovskaia, MD	Assistant Professor, Infectious Diseases Division Immunocompromised Infectious Diseases Physician Lead
Gina Askar, MD	Assistant Professor, Infectious Diseases Division Associate Program Director, Infectious Diseases Division
Ashley Huggett, DO	Assistant Professor, Infectious Diseases Division
Cheryl Newman, MD	Professor, Infectious Diseases Division
Rodger Macarthur, MD	Professor, Infectious Diseases Division
Hasan Samra, MD, D(ABMM), FACP	Director, Medical Microbiology Associate Program Director, Pathology Residency
Pamela Tipler, DO, FACP, DTM&H	Associate Professor of Medicine Travel Medicine Clinic Physician

## Compensation and Benefits

Residents enjoy a competitive stipend and generous benefits package including accrual of twenty-four days paid-time-off (PTO) as well as professional leave days for meeting attendance, individualized subsidized insurance starting day 1, free parking, and matching contributions to a 403-b retirement plan. The program pays resident travel expenses and registration fees to attend the ASHP Midyear Clinical Meeting and the Southeastern Residency Conference.



## Application Process

Applications are submitted electronically through the Pharmacy Online Residency Centralized Application Service (PhORCAS). Deadline for receipt of applications is January 2; however, early application is encouraged. On-site interviews are offered to a limited number of applicants based on review of the completed application in PhORCAS.

Applicants must possess a Pharm.D. degree from an ACPE-accredited college or school of pharmacy, have completed or be enrolled in an ASHP-accredited PGY1 program, and must be eligible for licensure as a pharmacist in the State of Georgia.

Application Material Includes:

1. Standardized application through PhORCAS (including letter of intent, CV, etc.)
2. At least 3 professional references through PhORCAS

For more information, refer to online information at <https://www.wellstar.org/pharmacy-residency/wmcg-health-pharmacy-residency-programs>

### Contacts:

Josh Eudy, PharmD, BCIDP  
Infectious Diseases Pharmacist  
PGY2 Infectious Diseases Residency Program Director  
Wellstar MCG Health  
1120 15th Street, AE 3024  
Augusta, GA 30912  
P: 706-721-7397  
[Joshua.Eudy@wellstar.org](mailto:Joshua.Eudy@wellstar.org)

Daniel Anderson, PharmD, BCIDP  
Assistant Professor Department of Pharmacology & Toxicology  
Assistant Professor Department of Medicine  
PGY2 Infectious Diseases Residency Program Coordinator  
Medical College of Georgia at Augusta University  
1434 Laney Walker Blvd, CB3630  
Augusta, GA 30912  
P: 706-721-1915  
[DANDERSON3@augusta.edu](mailto:DANDERSON3@augusta.edu)

## Recent Department Publications

- Evaluation of Sequential Oral Versus Intravenous Antibiotic Treatment of *Enterococcus faecalis* Bloodstream Infections. Ann Pharmacother. 2024;0(0)
- Evaluation of Short Versus Long Courses of Antibiotics in Critically Ill Patients with Gram-Negative Bloodstream Infections. Ann Pharmacother. Published online February 12, 2024
- Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observation Study. Infect Dis Ther. 2024;13(3):565-579.
- The prevalence of gram-negative bacteria with difficult-to-treat resistance and utilization of novel beta-lactam antibiotics in the southeastern United States. Antimicrob Steward Healthc Epidemiol. 2024 Mar 18;4(1):e35
- Evaluation of anti-methicillin-resistant *Staphylococcus aureus* (MRSA) prescribing habits in patients with a positive MRSA Nasal Swab in the absence of positive cultures. Pharmacy 2023; 11(3):81